中西医结合治疗慢性周围动脉闭塞性疾病

慢性周围动脉闭塞性疾病（PAO）治疗较为棘手。闭塞的血管不易再通，手术适应症范围小，且术后可能再度发生闭塞[1]。因此寻求适合的保守疗法非常重要。我院自1995年3月至1997年3月治疗PAO患者35例，其中23例用中药溶栓灵配合西药前列素E（PGE1）、天普乐欣（UK）治疗，与单纯用西药治疗的12例比较，疗效尚满意，现报道如下。1临床资料根据中国中西医结合研究会周围血管病专业委员会制定的诊断和分期标准[2]，收治35例PAO患者，包括血栓闭塞性脉管炎（TAO）19例，动脉硬化性闭塞（ASO）16例。随机分为两组：①溶栓灵结合PGEI、UK…     

放疗联合肝动脉化疗栓塞治疗肝癌的研究进展

对于不能手术的原发性肝癌患者，放射治疗配合肝动脉栓塞化疗（TACE）的疗效明显好于单纯放疗或单纯化疗，治疗并发症的发生率和程度可以接受，大多数患者可以耐受。放疗配合动脉栓塞化疗是治疗不能手术的原发性肝癌患者的非常有发展前途的治疗方法。现综述这二种治疗方法的技术特点、疗效和协同作用研究的现状及最新进展。     

Effects of exogenous sphinganine, sphingosine, and sphingosine-1-phosphate on relaxation and contraction of porcine thoracic aortic and pulmonary arterial rings.

Fumonisin mycotoxicosis in pigs causes a decrease in mean aortic pressure, an increase in mean pulmonary arterial pressure, and increases in serum concentrations of sphinganine (3.2 microM) and sphingosine (1.4 microM). To determine a causal relationship between the hemodynamic changes and sphingolipid alterations, we examined the in vitro effects of sphinganine, sphingosine, and sphingosine-1-phosphate on porcine aortic and pulmonary arterial rings. Both sphinganine and sphingosine relaxed un-contracted and phenylephrine-contracted aortic rings at > or = 10 microM and > or = 1 microM, respectively. Sphingosine (> or = 10 microM) relaxed un-contracted and phenylephrine-contracted pulmonary arterial rings, whereas sphingosine-1-phosphate (10 microM) contracted pulmonary arterial rings. Sphingosine (3 microM) also impaired the contractile response of pulmonary artery rings to 60 mM KCl. The results suggested that the systemic hypotension caused by fumonisin is mediated, in part, by increases in serum sphinganine and sphingosine concentrations, and the pulmonary hypertension is mediated, in part, by increased sphingosine-1-phosphate concentrations.     

单核细胞/淋巴细胞比值与糖尿病足患者下肢动脉病变的相关性研究

目的 探讨单核细胞/淋巴细胞比值（monocytes to lymphocytes ratio,MLR）与糖尿病足患者下肢动脉病变（lower extremity arterial disease,LEAD）的相关性。方法 选取2020年4月至2023年4月于陆军军医大学第一附属医院住院治疗的2 型糖尿病足患者243例,分为下肢动脉病变组（LEAD,n=103）和非下肢动脉病变组（non-lower extremity arterial disease,NLEAD,n=140）,分析MLR与LEAD的相关性。结果 LEAD组MLR显著高于NLEAD组［0.46（0.29,0.63） vs. 0.38（0.26,0.58）（P<0.05）］。logistic回归分析结果显示,MLR、年龄、胆固醇、血肌酐是糖尿病足患者发生下肢血管病变的影响因素（P<0.05）。受试者工作特征曲线分析表明,MLR预测糖尿病足患者下肢血管病变的最佳切点为0.34,敏感度和特异度分别为69.9%和46.4%。结论 MLR与2型糖尿病足患者LEAD的发生相关。     

化疗栓塞与化疗灌注在中晚期膀胱癌治疗中的对照研究

目的采用生存分析的方法对照研究化疗栓塞与化疗灌注在中、晚期膀胱癌中的治疗作用。资料与方法69例中、晚期膀胱癌患者分为两组,一组行双侧髂内动脉化疗灌注术,另一组行双侧髂内动脉化疗栓塞术。应用Cox比例风险模型对各个因素与术后膀胱癌的生存时间进行回归分析,筛选出主要的影响因素;应用Kaplan-Meier生存曲线分析两种治疗方法与生存时间的关系,并进行Log-Rank检验。结果69例手术均成功,双侧髂内动脉化疗栓塞术组生存时间为5~52个月,平均(26.52±3.29)个月;双侧髂内动脉化疗灌注术组生存时间为4~36个月,平均(13.41±1.69)个月。中晚期膀胱癌的死亡率与介入治疗的两种方法的相关性差异有统计学意义(P<0.05),其风险度为3.220,回归系数为1.169,证明双侧髂内动脉化疗栓塞术对于提高患者的生存时间具有更重要的意义。接受双侧髂内动脉化疗栓塞术的患者,生存时间明显高于接受双侧髂内动脉化疗灌注术的患者。结论应用化疗栓塞治疗较单纯化疗灌注治疗可明显提高患者的生存时间。     

Pulmonary artery-bronchus fistula treated with coil embolization

Bronchopulmonary arterial fistula consists of an abnormal connection between the bronchus and the vascular tree and is a rare but serious complication associated with a variety of lung interventions. We present a case of a 61-year-old female with a history of metastatic breast cancer treated with lumpectomy and radiation 20 years prior, who was found to have a fistula between the right pulmonary artery and the right mainstem bronchus. Our patient was treated endovascularly with coil embolization in the setting of massive hemoptysis flooding the trachea, which was successful in controlling the acute bleed, although care was withdrawn in the following days following a discussion with the family given the presence of advanced metastatic disease. This case illustrates the use of endovascular techniques to treat an actively bleeding bronchopulmonary arterial fistulae, including a review of the existing literature regarding the optimal endovascular management strategy. Although our patient did not achieve the best outcome, endovascular intervention with stent-placement or embolization can serve to temporarily halt blood flow through the fistula, stabilizing the patient and allowing for more radical therapy after improvement.     

多途径动脉灌注化疗及栓塞治疗对伴发远处转移的晚期妇科恶性肿瘤疗效初步分析

目的：探讨多途径动脉灌注化疗及栓塞治疗对已有远处脏器转移的妇科恶性肿瘤的效果。方法：对有肝、肺脏转移的晚期恶性肿瘤２９例进行了选择性盆腔动脉、肝动脉和肺动脉插管造影，继行化疗及栓塞治疗。结果：经治疗１５～３０ｄ后，２１例（７２．４％）病灶直径缩小５０％以上，５例（１７．２％）病灶直径缩小不足５０％，３例（１０．４％）治疗效果不明显。结论：多途径动脉灌注造影，行药物及栓塞治疗对有远处脏器转移的晚期恶性肿瘤有一定疗效，不仅有较强的局部作用，而且副作用较轻。但本组例数较少，随诊时间短，有关问题有待进一步研究。     

Increased oxytocinergic system activity in the cardiac muscle in spontaneously hypertensive SHR rats

IntroductionThe present study aimed to determine whether the presence of cardiac hypertrophy due to arterial hypertension is associated with a change in the activity of the oxytocinergic system in cardiomyocytes.Material and methodsThe experiments were performed on male, spontaneously hypertensive rats (SHR, n = 10) and normotensive Wistar-Kyoto rats (WKY, n = 12). Blood samples were collected from both SHR and WKY animals to asses plasma oxytocin (OT) concentration; the rats were sacrificed by decapitation. Samples of the left and right ventricles were harvested for the analysis of the OT and oxytocin receptor (OTR) protein by ELISA, and OT and OTR mRNA expression by RT-PCR. Immunohistopathological studies were performed to confirm the presence of OTR receptors in the cardiac muscle of the ventricles.ResultsPlasma OT concentration did not differ between SHR and WKY rats. In the SHR rats, the expression of OT mRNA and the OT protein level was higher in the left and the right ventricle, while OTR mRNA expression was significantly lower in both the left and the right ventricle. However, the level of OTR protein was higher only in the left ventricle of the SHR rats. The presence of OTR receptors was confirmed by immunohistochemical analysis in the muscle of the right and left ventricle.ConclusionsThe presence of arterial hypertension is associated with increased activity of the oxytocinergic system in the heart, especially in the area of the left ventricle. These findings support the important role of this system in the maintenance of cardiovascular homeostasis.     

Efficacy and safety of transcatheter arterial chemoembolization-lenvatinib sequential therapy for patients with unresectable hepatocellular carcinoma: a single-arm clinical study

BackgroundRepeated transcatheter arterial chemoembolization (TACE) could cause ischemia of the tumor tissue and increases production of angiogenic factors in patients with hepatocellular carcinoma (HCC). Lenvatinib can inhibit the expression of angiogenic factors induced by ischemia after TACE and reduce angiogenesis and tumor recurrence. TACE-lenvatinib sequential therapy may improve clinical outcomes. There have been few investigations of TACE-lenvatinib sequential therapy for the treatment of unresectable HCC. We aimed to evaluate the efficacy and safety of TACE-lenvatinib sequential therapy for unresectable HCC.MethodsFrom May 2018 to May 2021, 53 consecutive patients who underwent TACE-lenvatinib sequential therapy were retrospectively reviewed. Of these, 30 patients who met the inclusion criteria were selected. Lenvatinib treatment started within 1 or 2 weeks after TACE at a dose of 8 or 12 mg once daily. Treatment response was assessed using dynamic magnetic resonance imaging (MRI) according to the modified response evaluation criteria in solid tumor (mRECIST). Blood tests were also performed at every response evaluation. Patients with complete response (CR) or partial response (PR) and stable disease (SD) received continuous lenvatinib therapy, and patients with progressive disease (PD) received repeated TACE. The progression-free survival (PFS), overall survival (OS), objective response rate (ORR), disease control rate (DCR), and adverse events (AEs) were calculated. Statistical analysis was performed using the Kaplan-Meier method.ResultsThe median age was 58.5±9.1 years, and 16.7% (5/30) of patients were female. A total of 12 patients were categorized as Barcelona Clinic Liver Cancer (BCLC) Stage B and 18 were BCLC Stage C. The mean follow-up time was 15.7 months. The ORR was 76.7% (23/30), and the DCR was 96.7% (29/30). The median PFS was 6.1 months, and the median OS was 20.7 months. The most common lenvatinib-related AE was rash, and the most common TACE-related AE was elevated aspartate aminotransferase (AST). No treatment-related mortality was observed.ConclusionsFrom our findings, TACE-lenvatinib sequential therapy may prolong OS and PFS in patients with unresectable HCC, and the side effects are acceptable. The efficacy and safety of the sequential therapy should be confirmed in multiple center randomized controlled trials (RCTs) with a large sample and sufficient follow-up period.     

肢体动脉急性缺血22例

目的 探讨急性肢体动脉缺血(AEI)的病因、治疗及影响其预后的因素。方法 回顾性总结22例AEI患临床处理的经验。结果 手术处理21例占95．5％；非手术处理1例，肢体挽救率100％。结论 急诊手术对绝大多数AEI的病人有效。该病预后取决于早期诊断和及时治疗，对不同情况采取不同的处理措施。总的原则是尽快恢复缺血组织的血供；减少毒素吸收并注意保护多器官功能。